

Safety of Hydroxychloroquine in COVID-19

1 Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19

2
3 Sarah M Lofgren,¹ Melanie R Nicol,¹ Ananta S Bangdiwala,¹ Katelyn A Pastick,¹ Elizabeth C
4 Okafor,¹ Caleb P Skipper,¹ Matthew F Pullen,¹ Nicole W Engen,¹ Mahsa Abassi,¹ Darlisha A
5 Williams,¹ Alanna A Nascene,¹ Margaret L Axelrod,² Sylvain A Lothier,³ Lauren J MacKenzie,³
6 Glen Drobot,³ Nicole Marten,⁴ Matthew P Cheng,^{6,7} Ryan Zarychanski,^{3,4} Ilan S Schwartz,⁵
7 Michael Silverman,⁸ Zain Chagla,⁹ Lauren E Kelley,⁴ Emily G McDonald,^{6,7} Todd C Lee,^{6,7}
8 Katherine H Hullsiek,¹ David R. Boulware,¹ Radha Rajasingham.¹

9
10
11
12 1 University of Minnesota, Minneapolis, Minnesota
13 2 Vanderbilt University Medical Center, Nashville, Tennessee
14 3 Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba
15 4 George & Fay Yee Centre for Healthcare Innovation, Winnipeg, Manitoba
16 5 Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton,
17 Alberta
18 6 Research Institute of the McGill University Health Centre, Montreal, Quebec
19 7 Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal,
20 Quebec
21 8 Lawson Research Institute, St. Joseph's Healthcare Center, London, Ontario
22 9 McMaster University, Hamilton, Ontario

23
24
25
26 Keywords: Hydroxychloroquine, Covid-19, Safety, SARS-Cov2, Side-effects

27
28 Word Count: Total: 2802; Abstract 243

29
30
31 Corresponding author: Dr. Sarah Lofgren, 689 23rd Avenue S.E., Minneapolis, MN 55455;
32 Phone 612-624-4171; Lofg0020@umn.edu

33
34 Dr. Rajasingham is the Alternative Corresponding Author: radha@umn.edu

35
36 Clinicaltrials.gov Identifier:

37 NCT04308668 for post-exposure prophylaxis and early treatment trials.

38 NCT04328467 for pre-exposure prophylaxis trial.

40 41 Short Summary

Safety of Hydroxychloroquine in COVID-19

42 Data from three randomized clinical trials using hydroxychloroquine for the prevention and
43 treatment of COVID-19 did not suggest significant safety concerns. Gastrointestinal side effects
44 were common but arrhythmias were rare. There were no sudden deaths in any trial.
45

Safety of Hydroxychloroquine in COVID-19

46 **Abstract**

47 **Introduction:** Use of hydroxychloroquine in hospitalized patients with COVID-19, especially in
48 combination with azithromycin, has raised safety concerns. Here, we report safety data from
49 three outpatient randomized clinical trials.

50 **Methods:** We conducted three randomized, double-blind, placebo-controlled trials investigating
51 hydroxychloroquine as pre-exposure prophylaxis, post-exposure prophylaxis and early
52 treatment for COVID-19. We excluded individuals with contraindications to hydroxychloroquine.
53 We collected side effects and serious adverse events. We report descriptive analyses of our
54 findings.

55 **Results:** We enrolled 2,795 participants. The median age of research participants was 40 (IQR
56 34-49) years, and 59% (1633/2767) reported no chronic medical conditions. Overall 2,324
57 (84%) participants reported side effect data, and 638 (27%) reported at least one medication
58 side effect. Side effects were reported in 29% with daily, 36% with twice weekly, 31% with once
59 weekly hydroxychloroquine compared to 19% with placebo. The most common side effects
60 were upset stomach or nausea (25% with daily, 18% with twice weekly, 16% with weekly, vs.
61 10% for placebo), followed by diarrhea, vomiting, or abdominal pain (23% for daily, 16% twice
62 weekly, 12% weekly, vs. 6% for placebo). Two individuals were hospitalized for atrial
63 arrhythmias, one on placebo and one on twice weekly hydroxychloroquine. No sudden deaths
64 occurred.

65 **Conclusion:** Data from three outpatient COVID-19 trials demonstrated that gastrointestinal side
66 effects were common but mild with the use of hydroxychloroquine, while serious side effects
67 were rare. No deaths occurred related to hydroxychloroquine. Randomized clinical trials can
68 safely investigate whether hydroxychloroquine is efficacious for COVID-19.

69

Safety of Hydroxychloroquine in COVID-19

70 **Introduction:**

71 Hydroxychloroquine has *in vitro* antiviral activity against *Severe Acute Respiratory*
72 *Syndrome-related coronavirus 2* (SARS-CoV-2).[1, 2] While *in vitro* data suggest that both
73 chloroquine and hydroxychloroquine have activity against SARS-CoV-2 replication, the latter is
74 generally considered less toxic and better tolerated. However, clinical data to date demonstrate
75 no conclusive efficacy of hydroxychloroquine for the treatment or prevention of COVID-19.[3-5]
76 Both chloroquine and hydroxychloroquine impede SARS-CoV-2 replication.[2] Several
77 randomized placebo-controlled clinical trials are underway to evaluate hydroxychloroquine's
78 safety and efficacy in the prevention and treatment of COVID-19 in both inpatient and outpatient
79 populations.[6]

80 In late March 2020, hydroxychloroquine had substantial positive coverage in the media.
81 However, the tide rapidly turned due to concerted efforts to inform physicians and patients about
82 the potential risks of taking the drug outside of clinical trial settings.[7] Several inpatient
83 treatment studies then went on to show increased cardiac side effects with hydroxychloroquine
84 and azithromycin.[8, 9] On April 24th, 2020, the U.S Food and Drug Administration (FDA) issued
85 a caution against chloroquine and hydroxychloroquine in the treatment of COVID-19 outside of
86 hospital settings or clinical trials.[10] The FDA stated, "Hydroxychloroquine and chloroquine can
87 cause abnormal heart rhythms such as QT interval prolongation and...ventricular tachycardia."
88 The FDA noted that QT prolongation was more common among persons receiving azithromycin
89 and those with prior heart problems or kidney disease.

90 Hydroxychloroquine nonetheless has a 65-year track record of safety when prescribed at
91 recommended doses in populations with normal liver and kidney function, and without pre-
92 existing cardiac arrhythmias.[11] In the medical specialties of tropical medicine and
93 rheumatology, chloroquine and hydroxychloroquine have routinely been prescribed without
94 baseline laboratory testing or EKG monitoring. Whether these tests should be performed in the
95 setting of hydroxychloroquine for COVID-19 is controversial. As it stands, a number of ongoing

Safety of Hydroxychloroquine in COVID-19

96 clinical trials have been paused or halted by regulatory authorities over concerns related to the
97 potential for QT prolongation. Importantly, these safety concerns have risen from reports of
98 hydroxychloroquine use in hospitalized patients, who are more likely to have severe infections,
99 significant comorbidities and be on multiple concurrent medications.[12]

100 There are some features of the SARS-CoV-2 virus which may predispose individuals
101 with COVID-19 to be more likely to have complications from drugs that prolong the QT than
102 healthy individuals. SARS-CoV-2 itself can enter cardiomyocytes and may cause direct cardiac
103 injury.[13-15] Multiple reports of increased arrhythmias in individuals with COVID-19 without
104 other cause, suggest SARS-CoV-2 itself may cause arrhythmias.[15] Alternatively, elevated
105 cytokines directly or in concert with cardiomyocyte damage, may predispose to arrhythmias.[16]
106 Additionally, COVID-19 is associated with significant electrolyte imbalances, including sodium,
107 potassium, and calcium as well as renal failure, each of which also predispose individuals to
108 arrhythmias.[15, 17] Therefore testing the safety of hydroxychloroquine in individuals with
109 COVID-19 specifically is valuable.

110 The safety of hydroxychloroquine use for COVID-19 in outpatients has not been
111 established, but is believed to be less risky in outpatients than inpatients.[18] To address
112 current knowledge gaps regarding the safety and tolerability of hydroxychloroquine in the
113 outpatient prevention and treatment of COVID-19, and to inform its future usage in the setting of
114 clinical trials, we present the safety data from three randomized placebo-controlled clinical trials
115 of hydroxychloroquine in North America.

116

117 **Methods:**

118 *Study Design:*

119 We conducted three randomized, double-blind, placebo-controlled trials investigating
120 hydroxychloroquine as prophylaxis and treatment for COVID-19 disease. The first two trials

Safety of Hydroxychloroquine in COVID-19

121 evaluated: 1) post-exposure prophylaxis (PEP); 2) preemptive early treatment (PET),
122 (Clinicaltrials.gov Identifier: NCT04308668).[3, 19] Trial enrollment began on March 17, 2020,
123 concluded on May 6, and follow up was completed on May 20, 2020. The third trial assessed
124 pre-exposure prophylaxis (PREP) for COVID-19 (ClinicalTrials.gov Identifier: NCT04328467).
125 Enrollment for this third trial began April 6 and ended May 26, 2020, with follow-up concluding
126 on July 13, 2020.
127 In each of these trials, participants were randomized to receive placebo or hydroxychloroquine.
128 The PEP trial required participants to have a known exposure to a lab-confirmed COVID-19
129 case within four days either as a household contact or as a healthcare worker or first responder.
130 The PET trial enrolled persons with COVID-19 symptoms of four or fewer days duration and
131 either lab-confirmed SARS-CoV-2 or high-risk exposure to a known case within 14 days of
132 symptom onset. The PREP required persons to be high-risk healthcare workers or first
133 responders with ongoing occupational exposure to COVID-19.

134 Hydroxychloroquine dosing for both the PEP and PET trials was 800mg load dosing,
135 followed by 600mg in 6-8 hours, and then 600mg daily for five days in total. Participants were
136 instructed to split their follow-up dosing in the event of gastrointestinal upset. In designing the
137 trials, investigators chose doses within the existing FDA-approved dosing range that were
138 modeled to achieve therapeutic concentrations from day 1 through 10.[20] Hydroxychloroquine
139 dosing for PREP was dosed at 400 mg orally once, followed by 400mg 6 to 8 hours later,
140 thereafter 400mg weekly or twice weekly for the duration of follow-up, up to 12 weeks. The
141 placebo was dosed similarly.

142

Study Participants:

144 Participants were enrolled in the three trials via internet-based surveys throughout the
145 United States and selected Canadian provinces. Full details are online (Clinicaltrials.gov
146 Identifier: NCT04308668, NCT04328467).[3] Participants were excluded if they were <18 years

Safety of Hydroxychloroquine in COVID-19

147 old, had an allergy to hydroxychloroquine, retinal eye disease, known glucose-6 phosphate
148 dehydrogenase (G6PD) deficiency, known chronic kidney disease, stage 4 or 5 or receiving
149 dialysis, known porphyria, weight <40 kg, known QT prolongation, or receiving chemotherapy.
150 Current use of hydroxychloroquine, azithromycin, or cardiac arrhythmia medicines (flecainide,
151 amiodarone, digoxin, procainamide, propafenone, or sotalol) were also exclusion criteria. On
152 April 20, 2020, the FDA required additional exclusions of structural or ischemic heart disease
153 and personal or family history of cardiac QT prolongation, and medications that prolong the QTc
154 interval.

155 Health Canada mandated additional exclusions for Canadian participants. Women who
156 were pregnant or breastfeeding were excluded, as were patients with: severe diarrhea or
157 vomiting; known cirrhosis with a history of encephalopathy or ascites; known prolonged cardiac
158 QTc interval, history of ventricular arrhythmia or history of sudden cardiac death; patients taking
159 additional medicines that had a high risk of prolonging the electrocardiogram QTc interval in
160 conjunction with hydroxychloroquine. The Institutional Review Board (IRB) in Ontario also
161 mandated that a physician perform a complete review of medications for participants above age
162 65, to exclude those with important drug-drug interactions.

163 Participants in the PEP and PET trials completed follow-up email surveys on Days 1, 3,
164 5, 10, and 14, whereas participants in the PREP trial completed weekly follow-up surveys.
165 Surveys obtained self-report of study drug adherence, side effects, new COVID-19 symptoms,
166 new COVID-19 testing, and hospitalization. For participants who stopped their study drug due to
167 side effects or other reasons, we encouraged them to continue observational follow-up and
168 completion of self-report surveys.

169

170

171 *Statistical Analysis:*

Safety of Hydroxychloroquine in COVID-19

172 The analysis presented is primarily descriptive, summarizing the frequency of reported
173 medication side effects and medication-related serious adverse events, such as hospitalization,
174 life-threatening events, or deaths. With follow-up ongoing for the PREP study at the time of
175 publication, data through June 25, 2020, are included in this analysis.

176

177

178 *Approvals:*

179 IRB approval occurred at McGill University, Clinical Trials Ontario, University of
180 Manitoba, and University of Alberta, and the University of Minnesota.

181

182

183

184 **Results:**

185 A total of 2795 individuals were enrolled into the three trials. The combined median age
186 was 40 years (interquartile range [IQR] 34-49) and 51% were women. The median weight was
187 79 kg (IQR 66-91). The majority of participants (74%) were healthcare workers and first
188 responders. Approximately 66% of the participants were taking no chronic medications, and
189 59% had no chronic medical conditions. Demographic data are displayed in **Table 1**.

190

191 *Post-exposure prophylaxis and early treatment trials*

192 Of 1312 (n=821 PEP; n=491 PET) participants randomized, 87% (n=1139) started study
193 drug and completed follow-up surveys. Of 130 participants who started drug but did not
194 complete follow up, vital status was obtained for 32% (42/130), and all were alive. For the
195 remainder, we performed an internet search for death records and found none.

Safety of Hydroxychloroquine in COVID-19

196 Of 1139 who started study drug and reported side effect data, 29% reported one or
197 more side effects, with more side effects reported among those on hydroxychloroquine (40%)
198 versus placebo (18%) (**Table 2**). The most common side effects reported were upset stomach
199 or nausea (25% on hydroxychloroquine versus 9% on placebo), followed by vomiting, diarrhea,
200 or other GI symptoms (23% on hydroxychloroquine versus 6% on placebo), and neurologic
201 reactions, such as lightheadedness or dizziness (7% on hydroxychloroquine versus 5% on
202 placebo). Self-reported allergic reactions, occurred in 7 participants (6 on hydroxychloroquine
203 and 1 on placebo). There were no reported episodes of arrhythmias or sudden cardiac death.

204 Only 46 participants (4%) from the PEP and PET trials reported that they stopped the 5-
205 day treatment course due to side effects. The distribution of side effects was similar among both
206 trials. No serious adverse events, resulting in hospitalization, attributable to medication side
207 effects were reported.

208 Since gastrointestinal issues are known to occur in COVID-19, we compared side effects
209 between the placebo groups in the PEP group versus those who had COVID-19 in the PET
210 group. We did not identify a statistical difference in the incidence of nausea / upset stomach
211 reports in those with COVID-19 versus those exposed (11% vs. 8%, $p=0.12$). Similarly, the
212 incidence of diarrhea, abdominal pain, vomiting, or other gastrointestinal issues did not differ
213 between those with COVID-19 versus those exposed (7% vs. 4%, $p=0.14$). The risk of having
214 any side effects did not differ by sex, age group, weight, or if one was a healthcare worker or not
215 (**Table 3**).

216

Pre-exposure prophylaxis trial

218 Interim data June 25, 2020, demonstrated that of 1483 randomized, 1402 had follow up
219 data. Overall, 409 (29%) individuals experienced at least one side effect during the study (**Table**
220 **4**). Side effects were higher for those receiving hydroxychloroquine: 36% of those on twice-
221 weekly dosing, 31% on weekly dosing, and 21% on placebo reported at least one side effect.

Safety of Hydroxychloroquine in COVID-19

222 Similar to the other trials, the most common side effects reported were upset stomach or
223 nausea (18% on hydroxychloroquine twice weekly, 16% on hydroxychloroquine weekly, and
224 12% on placebo), followed by vomiting, diarrhea, or other GI symptoms (16% on
225 hydroxychloroquine twice weekly, 12% on hydroxychloroquine weekly, and 6% on placebo).
226 Two participants experienced atrial arrhythmias. One participant on placebo was hospitalized
227 twice with atrial fibrillation. Another participant on hydroxychloroquine twice weekly was
228 hospitalized after a syncopal event and was found to have a supraventricular tachycardia. No
229 ventricular arrhythmias were reported.

230 In total, across the three cohorts, 25 individuals have been hospitalized through June 25,
231 2020 (1% incidence). The PEP trial had two hospitalizations, one in each arm and no deaths.
232 The PET trial had 14 hospitalizations and two deaths. With hydroxychloroquine, 4
233 hospitalizations and 1 non-hospitalized death occurred. With placebo, 10 hospitalizations
234 occurred with one hospitalized death. Two hospitalizations were for non-COVID-19, non-study
235 medication related reasons, while the remaining 12 hospitalizations were due to COVID-19.
236 Nine individuals were hospitalized from the PREP study, one for COVID-19, two for arrhythmias
237 (one on hydroxychloroquine twice a day and one on placebo), and the other seven
238 hospitalizations were for non-study related reasons. No sudden unexplained deaths have been
239 reported in any of the three trials. Full details are in **Supplemental Table 1**.

240

Discussion:

242 Among 2464 participants reporting on side effects from 3 randomized clinical trials
243 investigating the efficacy of hydroxychloroquine in outpatient COVID-19 prevention and
244 treatment, 27% reported at least one medication-related side effect. We captured one episode
245 of supraventricular tachyarrhythmia with syncope in an individual on hydroxychloroquine and
246 two episodes of atrial fibrillation in one individual on placebo. Whether hydroxychloroquine was

Safety of Hydroxychloroquine in COVID-19

247 responsible or contributed to the development of the supraventricular tachycardia is unclear.
248 Hydroxychloroquine prolongs the QT interval and therefore is associated with an increased risk
249 of ventricular arrhythmias, not atrial arrhythmias. Regardless, atrial arrhythmias were rare in
250 both arms, and there were no episodes of ventricular arrhythmia or sudden death in
251 approximately 50,000 patient-days of cumulative exposure.

252 As expected, the most common side effects were nausea and gastrointestinal upset. In
253 addition to hydroxychloroquine, COVID-19 is also known to cause gastrointestinal upset.
254 However, when we compared the rate of gastrointestinal upset among those receiving placebo
255 in the post-exposure prophylaxis cohort versus those in the symptomatic cohort, reported
256 gastrointestinal side effects were not significantly more frequent. Most participants regarded
257 gastrointestinal upset as tolerable and completed the course of medication.

258 Medications causing QT prolongation are feared due to the risk of inducing ventricular
259 arrhythmias, yet reports of arrhythmias due to hydroxychloroquine use are most often reported
260 in the setting of co-ingestion, chronic use, or overdose.[21-23] The FDA does not recommend
261 hydroxychloroquine be used with other agents that prolong the QTc,[11] such as
262 azithromycin.[24] In 2017, the World Health Organization (WHO) reported that there has never
263 been a reported sudden cardiac death attributable to chloroquine when prescribed at malaria
264 treatment doses.[25] Despite the long history of chloroquine/hydroxychloroquine for malaria
265 treatment and rheumatological diseases such as lupus, there have been increasing concerns
266 around side effects in patients with COVID-19, especially related to arrhythmias.[26, 27] The
267 FDA has now changed their emergency use authorization recommendation for
268 hydroxychloroquine in COVID-19 treatment and prevention for this reason, among many others.
269 [10]

270 For context, a perspective on dosing is needed to understand potential risks with
271 chloroquine/hydroxychloroquine. Decades of safety data are available for the standard doses of
272 chloroquine used for malaria prophylaxis (500 mg [300 mg chloroquine base] weekly) and

Safety of Hydroxychloroquine in COVID-19

273 malaria treatment (2.5 g [1.5g chloroquine base] total over three days). Cardiac conduction
274 alterations were mostly seen when using much higher doses in hospitalized patients with
275 COVID-19 (12 g chloroquine base over 10 days).[9] The cumulative dose of
276 hydroxychloroquine-base used in our PEP and PET trials is 3.8 g (2.9 g base) total over 5 days.
277 This is in line with established safe dosing strategies and below the doses shown to cause
278 harmful effects.[28, 29] The Outcomes Related to COVID-19 Treated with Hydroxychloroquine
279 among In-patients with Symptomatic Disease (ORCID) trial used 400 mg twice on day one
280 followed by 200 mg twice daily for five days total (ClinicalTrials.gov Identifier: NCT04332991).
281 They enrolled 479 individuals and also found no significant safety concerns at that dose.[30]
282 Similarly, the RECOVERY trial used 2.4 g (1.86 g base) in four divided doses over 24 hours,
283 followed by 800 mg (620 mg base) for an additional 9 days or until discharge and they reported
284 no significant safety concerns in 11,000 hospitalized patients with COVID-19 randomized to
285 hydroxychloroquine or placebo.[31]

286 Our trials additionally excluded participants taking azithromycin and other QT-prolonging
287 drugs to enhance safety further. Other risk factors for QT prolongation, such as hypokalemia or
288 hypomagnesemia, are uncommon in outpatients.[32, 33] Mercurio, et al. found QTc prolongation
289 at 2.4 g courses of hydroxychloroquine over five days, but only clinically concerning side effects
290 when combined with azithromycin and side effects were more common among those already on
291 loop diuretics.[8] Our data showed one potential cardiac complication (atrial arrhythmia) in one
292 individual on hydroxychloroquine and one on placebo. Our potential rate of atrial arrhythmias
293 due to hydroxychloroquine is less than one in 1000. Many commonly used drugs, including
294 antibacterial, antifungal, and other antimalarial drugs, are known to prolong the QT, thereby
295 having a rare occurrence of arrhythmias.[34] The risk of QT prolongation has not precluded the
296 use of drugs such as ciprofloxacin or fluconazole in most patients, but has required clinicians
297 exercise caution.

Safety of Hydroxychloroquine in COVID-19

298 Despite our rational design of these clinical trials, several limitations still exist. A
299 significant limitation of our studies is related to their pragmatic nature, which relied on accurate
300 self-reporting. We did not prospectively record or evaluate for laboratory abnormalities or QTc
301 changes. While we have outcome data on 93% of participants who have completed the studies,
302 it is possible, given the passive nature of self-reported follow-up, that those lost-to-follow-up
303 may have had an adverse event that was not reported to our study team or their designated
304 emergency contacts. Additionally, our cohorts are relatively young, with a median age of 40.
305 They had few comorbidities and were on few medications. They were also predominantly
306 healthcare workers, comprising a population of individuals with high health literacy. All these
307 factors make our outpatient research participants healthier than most hospitalized patients in
308 North America. Finally, our study exclusively included outpatients. Patients admitted to hospital
309 are generally older and have more comorbidities. They also are more likely to have cardiac
310 complications of COVID-19 and thus may be more susceptible to develop adverse effects from
311 hydroxychloroquine.

312

313 Conclusion

314 While efforts towards the development of a vaccine continue, agents that can prevent
315 and treat COVID-19 are important. There is still equipoise concerning the potential efficacy of
316 hydroxychloroquine as an effective agent against COVID-19; thus, timely completion of
317 randomized placebo-controlled clinical trials is essential. Thus, large scale clinical trials to
318 carefully evaluate the limited potential therapeutics that have been identified and perhaps even
319 to replicate results of completed trials are imperative to our public health response. Ongoing
320 clinical trials can safely continue with research participants and regulatory bodies reassured as
321 to the general safety of hydroxychloroquine when using appropriate exclusion criteria.

322

Safety of Hydroxychloroquine in COVID-19

323 **Conflicts of Interest:** Authors are actively involved in clinical trials to prevent or treat COVID-
324 19. No author has a financial interest in remote EKG monitoring products or services.

325

326

327 **Acknowledgments**

328 This work was supported by Jan and David Baszucki, Steve Kirsch, the Alliance of
329 Minnesota Chinese Organizations, the Minnesota Chinese Chamber of Commerce, and the
330 University of Minnesota. Personnel was supported through the Doris Duke Charitable
331 Foundation through a grant supporting the Doris Duke International Clinical Research Fellows
332 Program at the University of Minnesota. Katelyn Pastick and Elizabeth Okafor are Doris Duke
333 International Clinical Research Fellows. Sarah Lofgren is supported by the National Institute of
334 Mental Health (K23MH121220). Caleb Skipper is supported by the Fogarty International Center
335 (D43TW009345). Drs. Melanie Nicol, Radha Rajasingham, and Matthew Pullen are supported
336 by the National Institute of Allergy and Infectious Disease (K08AI134262, K23AI138851,
337 T32AI055433). Margaret Axelrod is supported by NIH T32GM007347 and F30CA236157. Drs.
338 Lee and McDonald receive salary support from the Fonds de recherche du Québec – Santé.
339 Canadian funding was received from various sources. In Quebec, funds were received from the
340 Clinical Practice Assessment Unit of the McGill University Health Centre and the McGill
341 Interdisciplinary Initiative in Infection and Immunity's Emergency COVID-19 Research Funding.
342 In Manitoba, research support was provided from the Manitoba Medical Service Foundation. In
343 Alberta, support was provided by Northern Alberta Clinical Trials and Research Centre. In
344 Ontario, support was provided by the Research Institute of St. Joseph's Hamilton, the St
345 Joseph's Hospital Foundation in London, and Bridge to Health Medical and Dental. Purolator
346 Canada provided in-kind courier support for Canadian sites participating in the post-exposure
347 and early treatment trials. Apotex Pharmaceuticals Canada provided a donation of some of the
348 hydroxychloroquine tablets used. Rising Pharmaceutical donated some of the medicine for U.S.

Safety of Hydroxychloroquine in COVID-19

349 trials. COVID-19 Emergency Supplement funding was requested from the National Institutes of
350 Health for each of the three trials.

351

352

353 **References:**

- 354 1. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS
355 coronavirus infection and spread. *Virology* **2005**; 2: 69.
- 356 2. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized
357 Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory
358 Syndrome Coronavirus 2 (SARS-CoV-2). *Clinical infectious diseases : an official
359 publication of the Infectious Diseases Society of America* **2020**.
- 360 3. Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of
361 Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *The New England
362 journal of medicine* **2020**.
- 363 4. Pastick KA, Okafor EC, Wang F, et al. Review: Hydroxychloroquine and Chloroquine for
364 Treatment of SARS-CoV-2 (COVID-19). *Open Forum Infect Dis* **2020**; 7(4): ofaa130.
- 365 5. RECOVERY Trial. Statement from the Chief Investigators of the Randomised Evaluation
366 of COVID-19 thERapY (RECOVERY) Trial on hydroxychloroquine, 5 June 2020.
367 Available at: <https://www.recoverytrial.net/results>. Accessed 5 June 2020.
- 368 6. Cheng MP, Lee TC, Tan DHS, Murthy S. Generating randomized trial evidence to
369 optimize treatment in the COVID-19 pandemic. *CMAJ : Canadian Medical Association
370 journal = journal de l'Association medicale canadienne* **2020**; 192(15): E405-E7.
- 371 7. Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and
372 azithromycin in the management of SARS-CoV-2 infection. *CMAJ : Canadian Medical
373 Association journal = journal de l'Association medicale canadienne* **2020**; 192(17): E450-
374 E3.
- 375 8. Mercurio NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation Associated With
376 Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among
377 Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). *JAMA
378 Cardiol* **2020**.
- 379 9. Borba MGS, Val FFA, Sampaio VS, et al. Effect of High vs Low Doses of Chloroquine
380 Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute
381 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. *JAMA Network Open*
382 **2020**; 3(4): e208857-e.
- 383 10. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of
384 the hospital setting or a clinical trial due to risk of heart rhythm problems. Available at:

Safety of Hydroxychloroquine in COVID-19

- 385 [https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-](https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or)
386 [hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or.](https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or)
- 387 11. Hydroxychloroquine FDA Package Insert. Available at:
388 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf. Accessed May 1, 2020.
389
- 390 12. Ross SB, Wilson MG, Papillon-Ferland L, et al. COVID-SAFER: Deprescribing Guidance
391 for Hydroxychloroquine Drug Interactions in Older Adults. *Journal of the American*
392 *Geriatrics Society* **2020**.
- 393 13. Guo J, Wei X, Li Q, et al. Single-cell RNA analysis on ACE2 expression provides
394 insights into SARS-CoV-2 potential entry into the bloodstream and heart injury. *J Cell*
395 *Physiol* **2020**.
- 396 14. Sharma A, Garcia G, Arumugaswami V, Svendsen CN. Human iPSC-Derived
397 Cardiomyocytes are Susceptible to SARS-CoV-2 Infection. *bioRxiv* **2020**.
- 398 15. Wu L, O'Kane AM, Peng H, Bi Y, Motriuk-Smith D, Ren J. SARS-CoV-2 and
399 cardiovascular complications: From molecular mechanisms to pharmaceutical
400 management. *Biochem Pharmacol* **2020**; 178: 114114.
- 401 16. Dhakal BP, Sweitzer NK, Indik JH, Acharya D, William P. SARS-CoV-2 Infection and
402 Cardiovascular Disease: COVID-19 Heart. *Heart Lung Circ* **2020**.
- 403 17. Lippi G, South AM, Henry BM. Electrolyte imbalances in patients with severe
404 coronavirus disease 2019 (COVID-19). *Ann Clin Biochem* **2020**; 57(3): 262-5.
- 405 18. Sacher F, Fauchier L, Boveda S, et al. Use of drugs with potential cardiac effect in the
406 setting of SARS-CoV-2 infection. *Arch Cardiovasc Dis* **2020**; 113(5): 293-6.
- 407 19. Lothar SA, Abassi M, Agostinis A, et al. Post-exposure prophylaxis or pre-emptive
408 therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study
409 protocol for a pragmatic randomized-controlled trial. *Canadian journal of anaesthesia =*
410 *Journal canadien d'anesthesie* **2020**.
- 411 20. Al-Kofahi M, Jacobson P, Boulware DR, et al. Finding the dose for hydroxychloroquine
412 prophylaxis for COVID-19: The desperate search for effectiveness. *Clinical*
413 *pharmacology and therapeutics* **2020**.
- 414 21. Cheng WF, Kao NC, Tsao KH, Chen CJ, Sun TJ, Wang YC. The Inhibition of
415 Immunologic Response by Chloroquine. *Chin Med J* **1964**; 83: 531-5.
- 416 22. Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A
417 narrative review for emergency providers. *Am J Emerg Med* **2020**.
- 418 23. Morgan ND, Patel SV, Dvorkina O. Suspected hydroxychloroquine-associated QT-
419 interval prolongation in a patient with systemic lupus erythematosus. *Journal of clinical*
420 *rheumatology : practical reports on rheumatic & musculoskeletal diseases* **2013**; 19(5):
421 286-8.

Safety of Hydroxychloroquine in COVID-19

- 422 24. Hancox JC, Hasnain M, Vieweg WV, Crouse EL, Baranchuk A. Azithromycin,
423 cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory
424 issues: A narrative review based on the study of case reports. *Ther Adv Infect Dis* **2013**;
425 1(5): 155-65.
- 426 25. The cardiotoxicity of antimalarials. In: *Malaria Policy Advisory Committee Meeting*.
427 Geneva, Switzerland: World Health Organization (WHO), 2017:1-49.
- 428 26. Glenza J. Brazilian chloroquine study halted after high dose proved lethal for some
429 patients. Available at: [https://www.theguardian.com/world/2020/apr/24/chloroquine-](https://www.theguardian.com/world/2020/apr/24/chloroquine-study-coronavirus-brazil)
430 [study-coronavirus-brazil](https://www.theguardian.com/world/2020/apr/24/chloroquine-study-coronavirus-brazil).
- 431 27. Shaw ML. Caution Strongly Recommended When Using Chloroquine,
432 Hydroxychloroquine in Patients With Cardiovascular Disease, COVID-19. Available at:
433 [https://www.ajmc.com/newsroom/caution-strongly-recommended-when-using-](https://www.ajmc.com/newsroom/caution-strongly-recommended-when-using-chloroquine-hydroxychloroquine-in-patients-with-cardiovascular-disease-covid19)
434 [chloroquine-hydroxychloroquine-in-patients-with-cardiovascular-disease-covid19](https://www.ajmc.com/newsroom/caution-strongly-recommended-when-using-chloroquine-hydroxychloroquine-in-patients-with-cardiovascular-disease-covid19).
- 435 28. Ding HJ, Denniston AK, Rao VK, Gordon C. Hydroxychloroquine-related retinal toxicity.
436 *Rheumatology (Oxford)* **2016**; 55(6): 957-67.
- 437 29. Munster T, Gibbs JP, Shen D, et al. Hydroxychloroquine concentration-response
438 relationships in patients with rheumatoid arthritis. *Arthritis Rheum* **2002**; 46(6): 1460-9.
- 439 30. Major US Trial Closes Showing No Benefit for Hydroxychloroquine in COVID-19.
- 440 31. Horby P LM. Correspondence to All RECOVERY Principal Investigators.
441 [https://www.recoverytrial.net/files/professional-](https://www.recoverytrial.net/files/professional-downloads/recovery_noticetoinvestigators_2020-05-24_1422.pdf)
442 [downloads/recovery_noticetoinvestigators_2020-05-24_1422.pdf](https://www.recoverytrial.net/files/professional-downloads/recovery_noticetoinvestigators_2020-05-24_1422.pdf): RECOVERY Central
443 Coordinating Office, **2020**:2.
- 444 32. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for Drug Interactions
445 on QTc Interval in Exploratory COVID-19 Treatment. *Heart Rhythm* **2020**.
- 446 33. Sapp JL, Alqarawi W, MacIntyre CJ, et al. Guidance on Minimizing Risk of Drug-Induced
447 Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian
448 Heart Rhythm Society. *The Canadian journal of cardiology* **2020**; 36(6): 948-51.
- 449 34. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. *Heart* **2003**;
450 89(11): 1363-72.
- 451
- 452
- 453

Safety of Hydroxychloroquine in COVID-19

454 **Table 1. Baseline Demographics for all three cohorts, Post-exposure Prophylaxis,**
455 **Preemptive Early Treatment, and Pre-exposure prophylaxis**

Demographic	N (%) or Median, [IQR]
Participants	2795
Age in years, median [IQR]	40 [34, 49]
Weight in kg, median [IQR]	79 [66, 91]
Women, N (%)	1423 (51.4%)
Ethnicity (all that apply), N (%)	
White or Caucasian	1972 (71.3%)
Black or African American	72 (2.6%)
Asian or South Asian	527 (19.0%)
Hispanic or Latino	132 (4.8%)
Native American or Pacific Islander	36 (1.3%)
Other or Not Stated	68 (2.5%)
Healthcare worker/First Responder, N (%)	2059 (74.4%)
Current smoker, N (%)	80 (2.9%)
No medications listed, N (%)	1825 (66.0%)
No chronic medical conditions, N (%)	1633 (59.0%)

IQR= Interquartile Range

456
457
458

Safety of Hydroxychloroquine in COVID-19

Table 2. Combined Side Effects Days 1-5 in Post-Exposure Prophylaxis and Early Treatment Cohorts

	Hydroxychloroquine	Placebo	P-value*
Number randomized	658	654	
Started study medication	576 (87.5%)	563 (86.1%)	0.46
Any side effect (days 1-5)**	231 (40.1%)	101 (17.9%)	<0.001
Side Effects**			
Nausea or upset stomach	146 (25.3%)	53 (9.4%)	<0.001
Diarrhea, abdominal pain, vomiting	131 (22.7%)	35 (6.2%)	<0.001
Irritability, dizziness, vertigo	39 (6.8%)	26 (4.6%)	0.13
Tinnitus	16 (2.8%)	8 (1.4%)	0.15
Headache	15 (2.6%)	8 (1.4%)	0.21
Visual changes	7 (1.2%)	5 (0.9%)	0.77
Skin reaction	10 (1.7%)	4 (0.7%)	0.18
Taste change or dry mouth	3 (0.5%)	3 (0.5%)	>0.99
Allergic reaction	6 (1.0%)	1 (0.2%)	0.12
Hot flashes, night sweats or palpitations	2 (0.3%)	1 (0.2%)	>0.99
Fatigue	1 (0.2%)	1 (0.2%)	>0.99
Panic	0 (0.0%)	1 (0.2%)	0.49
Other	1 (0.2%)	2 (0.4%)	0.62

*P values calculated via Fisher's Exact test. **Of those who started study medication.

Safety of Hydroxychloroquine in COVID-19

Table 3. Odds of Side Effects in Post-exposure Prophylaxis and Early Treatment Cohorts.

Group	Odds Ratio of Any Side Effect	95% Confidence Interval	P-value*
Women vs. Men	1.163	0.827-1.637	0.39
Healthcare Worker vs. Not	0.796	0.570-1.111	0.18
Age < 35 compared with 35-50 years	1.055	0.707-1.576	0.79
Age > 50 compared with 35-50 years	0.726	0.457-1.151	0.17
Weight < 64kg compared with 64-87 kg	1.421	0.911- 2.218	0.12
Weight > 87kg compared with 64-87 kg	0.744	0.470-1.179	0.21

*P value calculated via Chi-Square

Safety of Hydroxychloroquine in COVID-19

Table 4. Side Effects from Pre-exposure Prophylaxis Cohort through June 25, 2020

	Hydroxychloroquine 2x per week	Hydroxychloroquine 1x per week	Placebo	P-value*
Number randomized	495	494	494	
Number with completed Surveys	462	471	469	
Any side effect**	167 (36.2%)	145 (30.8%)	97 (20.7%)	<0.001
Side Effects**				
Nausea or upset stomach	85 (18.4%)	77 (16.3%)	54 (11.5%)	0.04
Diarrhea, abdominal pain, vomiting	75 (16.2%)	56 (11.9%)	30 (6.4%)	<0.001
Arrhythmia, tachycardia, palpitations	8 (1.7%)	8 (1.7%)	11 (2.3%)	0.73
Irritability, dizziness, vertigo	23 (5.0%)	25 (5.3%)	22 (4.7%)	0.92
Tinnitus	6 (1.3%)	10 (2.1%)	4 (0.9%)	0.26
Fatigue	4 (0.9%)	0 (0.0%)	1 (0.2%)	-
Visual changes	4 (0.9%)	7 (1.5%)	3 (0.6%)	0.41
Skin reaction	22 (4.8%)	11 (2.3%)	10 (2.1%)	0.04
Allergic reaction	4 (0.9%)	2 (0.4%)	3 (0.6%)	0.70
Sleep disturbance	6 (1.3%)	8 (1.7%)	4 (0.9%)	0.52
Myalgia	1 (0.2%)	4 (0.8%)	2 (0.4%)	0.38
Arrhythmias	1(0.2%)	0 (0.0%)	1 (0.2%)	-
Other	14 (3.0%)	10 (2.1%)	5 (1.1%)	0.12

*P values calculated via Fisher's Exact Test comparing hydroxychloroquine (pooled) versus placebo. **Of participants who completed surveys